Pulmonary Arterial Hypertension

Category icon
Balloon Pulmonary Angioplasty: State of the Art

John G Coghlan, Alexander MK Rothman, Stephen P Hoole,

Category icon
Vascular Access and Chronic Total Occlusion Angioplasty

David Smith, Ahmed Hailan, Alexander Chase,

Category icon
Vascular Access and Chronic Total Occlusion Angioplasty

David Smith, Ahmed Hailan, Alexander Chase,

Category icon
Balloon Pulmonary Angioplasty: State of the Art

John G Coghlan, Alexander MK Rothman, Stephen P Hoole,

About

Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.

PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.

Related Articles

Articles

Balloon Pulmonary Angioplasty: State of the Art

John G Coghlan, Alexander MK Rothman, Stephen P Hoole,

Published:

Citation: Interventional Cardiology Review 2021;16:e02.

Vascular Access and Chronic Total Occlusion Angioplasty

David Smith, Ahmed Hailan, Alexander Chase,

Citation: Interventional Cardiology Review 2015;10(2):90–3